Weight-Loss Jabs Show Promise in Reducing Cancer Risk

Weight-Loss Jabs Show Promise in Reducing Cancer Risk

A landmark study presented at the European Congress on Obesity in Malaga, Spain, suggests that weight-loss jabs could almost halve the risk of obesity-related cancers. Researchers from Tel Aviv University found that bariatric surgery reduces the risk of cancer by 30-42%. However, when accounting for weight loss, newer medications were more effective at preventing obesity-related cancer than bariatric surgery.

Key Findings

  • Efficacy of New Medications:

    • According to Prof. Dror Dicker from Hasharon Hospital Rabin Medical Center, new generation highly potent GLP-1 receptor agonists (GLP-1RAs) may offer greater advantages in reducing the risk of obesity-related cancers.
    • Future research is needed to ensure these drugs do not increase the risk of non-obesity-related cancers.
  • Comparative Study Results:

    • A separate study published online ahead-of-print by NEJM showed that Mounjaro produced significantly better results than Wegovy.
    • Patients taking Mounjaro lost about 50% more body mass compared to Wegovy participants, which is roughly equivalent to 5 kg (11 lbs).
    • The mean percentage change from baseline body weight loss was:
      • Mounjaro: -20.2%
      • Wegovy: -13.7%

Expert Insights

Professor Mark Lawler, an internationally renowned cancer research expert from Queens University Belfast, stated:

"These data suggest that target GLP-1s may cut obesity-related cancer risks by nearly half—a finding which would be transformational."

He emphasized the need for further research on the mechanisms involved, noting that these findings raise intriguing possibilities for preventive medicine, potentially preventing multiple cancers across general populations, including common types such as breast and colon cancer, as well as more challenging ones like pancreatic and ovarian cancer.

This work heralds a whole new era in preventive medicine.

FacebooktwitterlinkedinrssyoutubeFacebooktwitterlinkedinrssyoutube
FacebooktwitterredditpinterestlinkedinmailFacebooktwitterredditpinterestlinkedinmail

Leave a Comment

Your email address will not be published. Required fields are marked *